Jubilant Therapeutics is developing potent and selective small molecule modulators to address specific unmet medical needs in oncology and autoimmune diseases. Using their Therapeutic Index and Brain Exposure Optimization (TIBEO) discovery engine, Jubilant is integrating structure-based design and computational algorithms to discover and develop novel, precision therapeutics that have enhanced brain penetration. Jubilant’s lead candidate, JBI-802, targets an epigenetic modulator and is being tested for neuro-endocrine tumors.

Jubilant Therapeutics

Founded: 2019
Location: Bedminster, NJ
Employee range: 11 - 50
Clinical stage: Clin1/Clin2
Therapy area: neuroendocrine tumors
Drug types: ONC, IMM
Lead product: JBI-802
Funding: not disclosed

Drug notes:

About:

Jobs: